The tweet was deleted by the author.
But we saved everything 🙂.
Outlook Therapeutics is accelerating work on innovative ophthalmic therapies aimed at improving care for patients with retinal diseases.
The company states that preserving vision remains its core mission as it focuses research and development on solutions for conditions such as wet age-related macular degeneration. The ongoing innovation highlights the growing need for advanced treatments in ophthalmology and reflects the industry trend toward addressing unmet medical needs in eye care.
Outlook Therapeutics recently resubmitted its Biologics License Application to the U.S. Food and Drug Administration for ONS-5010, a treatment targeting retina diseases, according to a company statement earlier this year. The company also launched a $5 million registered direct offering priced at the market under Nasdaq rules in a separate move. These actions come as Outlook Therapeutics ramps up its development efforts in retinal care.